Sharing of Second-Half Business Priorities and AI Special Lecture Held
"Growing Together with Our Customers Through Innovation and Distinctive Expertise"
[E-Daily Reporter Hyera Lee ] Kyobo Securities ( KYOBOSECURITIESCO.,LTD.(030610)) announced on the 10th that it held the “Second Half of 2026 Management Strategy Meeting and Vision 2030 Proclamation Ceremony” the previous day at the Bulls Hall of the Korea Financial Investment Association in Yeouido, Seoul. Lee Seok-ki, CEO of KYOBOSECURITIESCO.,LTD., is delivering remarks at the second-half management strategy meeting and “Vision 2030” proclamation ceremony held on the 9th. (Photo = KYOBOSECURITIESCO.,LTD.) The event was attended by approximately 120 executives, department heads, and branch managers, including CEO Lee Seok-ki. Participants reviewed first-half business performance and financial status and shared key initiatives for each business division. Additionally, the company invited AI business expert Park Seong-hyeok to deliver a special lecture titled “Rediscovering the Securities Industry in the Age of AX (Artificial Intelligence Transformation),” during which they discussed the direction of digital transformation in the financial industry. At the subsequent “Vision 2030” declaration ceremony, KYOBOSECURITIESCO.,LTD. announced its new vision: “A comprehensive financial investment partner that grows alongside customers through innovation and differentiated expertise.” Based on this vision, KYOBOSECURITIESCO.,LTD. plans to focus on strengthening future-oriented business capabilities, pursuing partnership-based value rooted in trust, and enhancing the competitiveness of its investment solutions. CEO Lee stated, “Under this new vision, we will solidly build our core business portfolio to establish a sustainable growth model.”
(Photo: Blind)
One of the concerns facing the Lee Jae-myung administration is the decline in support among young people. According to Gallup Korea’s presidential job approval ratings, the approval…
The KRX Health Care Index rose 4.53% from the previous session on Oct. 1, signaling a rare tailwind for South Korea’s pharmaceutical and biotech sector. Among the gainers, GIInnovation and G2GBio drew…
(Graphic: ChatGPT)
“While existing ex vivo chimeric antigen receptor T-cell (CAR-T) therapies are personalized treatments that require cell collection from each patient for manufacturing, the in v…
